C
CIN Terminal
Cannabis Investor News
A CanIDeal, Inc. Company
J
Live
Loading market data...
Expand
Symbol Name Exchange Last Change Volume Watch
Home Markets Loading…
TLRY Canadian LP

Tilray Brands

NASDAQ · TLRY

Global cannabis and consumer goods company. Largest cannabis company by revenue globally with operations in 20+ countries.

$4.54
+8.10%
Live Price
Price History 5 Years

Analyst Coverage

Cannabis Investor News in-house rating · cin-analyst-v1.0

Neutral Conviction 1/5
49/100 composite
Fundamentals53
Regulatory66
Market40
Editorial30
Composite · trailing 12 months

Tilray Brands earns a Neutral rating with a composite score of 49.45, reflecting balanced strengths in its Canadian regulatory environment against persistent operational headwinds and absent market liquidity. The company operates from a jurisdiction rated at 80 on regulatory posture, benefiting from Canada's established framework and delivering a clean enforcement record. This regulatory clarity lifts the pillar to 65.5, the firmest contributor to the overall profile. However, fundamentals remain challenged at 53.08. Revenue contracted 7.8 percent year-over-year while gross margin stands at 27.7 percent—modest but insufficient to offset an operating margin of negative 52.7 percent. Positive EBITDA provides cash runway stability and supports a market capitalization near $546 million, yet the combination of shrinking top-line growth and ongoing operating losses constrains the upside case.

Market dynamics present a more acute concern, scoring only 40.0 due to unavailable quote data, which signals either delisting risk or severe illiquidity that complicates price discovery and investor access. Editorial coverage registers at 30.0 with zero newsroom or brief mentions, indicating Tilray has drifted from the attention economy that often catalyzes sector re-ratings. The low conviction score of 1 out of 5 underscores the narrow margin between competing factors: regulatory tailwinds versus fundamental execution gaps and market invisibility.

The most critical signal to monitor is whether Tilray can stabilize or reverse revenue decline in the next two quarters, as any sustained top-line momentum would tighten operating losses and potentially restore market confidence, lifting the composite score toward the Overweight threshold.

Scored: 2026-07-14Valid through: 2026-08-28Weights: Fundamentals 35% · Regulatory 25% · Market 25% · Editorial 15%
Loading CIN Rating…
Fundamentals SEC & Market Data
Loading fundamentals…
Analyst Consensus
Loading analyst data…
Valuation Multiples
Loading…
Price Statistics
Loading…
Financing Activity
Loading financing data…
Insider Transactions
Loading insider data…
Regulatory Filings
Loading regulator disclosures…
Peer Comparison
Loading peer data…
Institutional DetailIR, corporate, and filing data from CIN enrichment
IR & AgencyInvestor relations
Corporate DetailsCompany profile
Headquarters
655 MADISON AVENUE, 19TH FLOOR, NEW YORK, NY, 10065
Phone
519.322.8800
CEO
Irwin D. Simon
CFO
Carl Merton
SEC CIK
1731348
Website
Company website
Fundamentals & FinancialsRefreshed nightly from licensed fundamentals data
Market cap
$545.7M
Enterprise value
$641.6M
Price to book
0.35
Price to sales
0.64
EV / EBITDA
-4.84
Revenue (TTM)
$858.3M
Gross profit (TTM)
$237.6M
EBITDA
$17.8M
Operating margin
-52.7%
Profit margin
-156.7%
Rev growth YoY
-7.8%
Return on equity
-63.2%
Return on assets
-1.5%
EPS (TTM)
$-14.63
EPS est. current year
$-0.11
Wall St. target price
$9.55
Shares outstanding
123.5M
Insider ownership
0.7%
Institutional ownership
9.4%
Beta
1.90
Full-time employees
2,842
GICS sector
Healthcare
GICS industry
Drug Manufacturers - Specialty & Generic
Filings & DisclosuresPrimary sources
Annual report
Latest 10-K
Proxy statement
Latest DEF 14A
Filing portal
SEDAR+
See something incorrect or missing?

Help us keep coverage accurate. Submit an update for CIN editorial review.

Submit an update
Complimentary Research
Would you like a deeper analysis on this company?

Request a complimentary, fully customized institutional-quality research report — tailored to your investment thesis.

Request Complimentary Report

Bullish and Bearish Analyst Opinions for Tilray Brands (TLRY)

Cannabis Investor News aggregates analyst coverage, price targets, insider transactions, SEC filings, and financing activity for Tilray Brands (TLRY), a cannabis-sector equity listed on NASDAQ in the Canadian LP category. Use this profile to compare bullish and bearish opinions, monitor Form 4 insider buys and sells, and review the latest quarterly results.

Analyst average price target $7.47.

CIN editorial stance: Event-Driven Opportunity. Setup improving. Strong session detected. (5 bullish signals, 3 bearish signals.)

Global cannabis and consumer goods company. Largest cannabis company by revenue globally with operations in 20+ countries.

Latest price: $4.54 (+8.10%) on NASDAQ.

Historical Price Data

5-year weekly price history, intraday quotes, and 52-week range for TLRY are maintained by Cannabis Investor News and refreshed throughout the trading day.